Expert Opinion on the Role of Dapagliflozin in Cardiometabolic Diseases: An Indian Perspective

Cardiometabolic Disease (CMD) is a growing health concern worldwide, including in India, characterized by a constellation of factors such as metabolic syndrome, obesity, dyslipidemia, diabetes, prediabetes, Non-Alcoholic Fatty Liver Disease (NAFLD), and Chronic Kidney Disease (CKD).Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) such as dapagliflozin, have demonstrated promising pleiotropic effects beyond the glycemic efficacy, including improving cardiovascular and renal outcomes in patients with CMD.This article aims to explore the potential of dapagliflozin in managing the full spectrum of CMD based on the expert opinions of diabetologists and endocrinologists.The document discusses the role of SGLT2is across the cardiometabolic spectrum such as prediabetes and diabetes, obesity, hypertension, NAFLD, CKD, Cardiovascular Disease (CVD), and heart failure, and the evidence supporting their use in CMD.